financetom
Business
financetom
/
Business
/
Agricultural equipment maker Lindsay misses Q4 revenue estimates, sees soft demand 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Agricultural equipment maker Lindsay misses Q4 revenue estimates, sees soft demand 
Oct 23, 2025 4:22 AM

Overview

* Lindsay Q4 revenue misses analyst expectations, down 1% yr/yr

* International irrigation revenues up 23%, driven by South America and MENA region

* Infrastructure revenues down 16% due to lower Road Zipper System sales

Outlook

* Company expects North American irrigation demand to remain tempered due to commodity price pressure

* Lindsay anticipates stable growth in Road Zipper System leasing and road safety products

* Company sees continued growth in Brazil despite high interest rates and credit constraints

Result Drivers

* INTERNATIONAL IRRIGATION GROWTH - Strong growth in South America and MENA region boosts international irrigation revenues

* NORTH AMERICA IRRIGATION DECLINE - Lower storm damage replacement demand and soft market conditions impact North America irrigation revenues

* INFRASTRUCTURE REVENUE DECREASE - Infrastructure revenues down due to absence of prior year Road Zipper System project sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Miss $153.60 $156.91

Revenue mln mln (4

Analysts

)

Q4 EPS $0.99

Q4 Net $10.80

Income mln

Q4 $11.30

Operatin mln

g Income

Q4 7.40%

Operatin

g Margin

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Arista Networks Unusual Options Activity
Arista Networks Unusual Options Activity
Jul 8, 2025
Investors with a lot of money to spend have taken a bearish stance on Arista Networks ( ANET ) . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this...
Factbox-Trump tariff talks: the state of play with top trading partners
Factbox-Trump tariff talks: the state of play with top trading partners
Jul 8, 2025
WASHINGTON (Reuters) -U.S. President Donald Trump has ramped up his trade war this week, threatening sharply higher tariffs on 14 countries starting August 1 as his administration aims to finalize agreements with others. Despite promises to work on 90 deals in 90 days, Trump and his team have been able to complete only a limited deal with Britain and a...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Longeveron Gets US FDA Approval for Phase 2 Trial of Laromestrocel
Longeveron Gets US FDA Approval for Phase 2 Trial of Laromestrocel
Jul 8, 2025
11:04 AM EDT, 07/08/2025 (MT Newswires) -- Longeveron ( LGVN ) said Tuesday the US Food and Drug Administration has cleared its investigational new drug application for stem cell therapy laromestrocel as a potential treatment for pediatric dilated cardiomyopathy. The company said it plans to begin phase 2 clinical trials in H1 2026. There are currently no approved therapies for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved